The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors.
Amishi Shah
No relevant relationships to disclose
Shweta Motiwala
No relevant relationships to disclose
Marcia S. Brose
Consultant or Advisory Role - Bayer/Onyx
Research Funding - Bayer/Onyx
Peter J. O'Dwyer
Research Funding - Bayer/Onyx
Keith Flaherty
Research Funding - Bayer/Onyx
Stephen Michael Keefe
No relevant relationships to disclose